Author

M. Verdoes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Approach:genetic perturbation / CRISPR· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:protein folding & dynamics· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:CITE-seq· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. G. Figdor· 4 shared C. M. Le Gall· 3 shared A. Cammarata· 2 shared A. M. D. Becker· 2 shared D. van Dalen· 2 shared F. A. Scheeren· 2 shared I. Ramos-Tomillero· 2 shared M. Valente· 2 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

C. G. Figdor

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Immunofilaments Provide a Nanoscale Platform for In Vivo T Cell Expansion and Cancer Immunotherapy

L. Weiss, J. Weiden, Y. Dölen, E. Grad, E. A. W. van Dinther, M. Schluck, L. J. Eggermont, G. van Mierlo, U. Gileadi, A. Bartolo-Ibars, R. Raave, M. A. J. Gorris, K. Verrijp, M. Valente, B. Deplancke, , R. Hammink

This paper introduces immunofilaments that expand T cells in vivo, showing efficacy against melanoma when combined with immune checkpoint blockade.

bioRxiv · Oct 14, 2022Immunology

Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion

C. M. Le Gall, A. Cammarata, L. de Haas, I. Ramos-Tomillero, J. Cuenca-Escalona, Z. Wijfjes, A. M. D. Becker, Y. Dolen, I. J. M. de Vries, C. G. Figdor, G. Florez-Grau, M. Verdoes

This study demonstrates that targeting NY-ESO-1 antigen to human cDC1s via XCL1(CC3) enhances cross-presentation and CD8+ T cell activation.

bioRxiv · Nov 30, 2021Immunology

Dual site-specific chemoenzymatic antibody fragment conjugation using CRISPR-based hybridoma engineering

C. M. Le Gall, J. M. van der Schoot, I. Ramos-Tomillero, M. Parlak Khalily, F. J. van Dalen, Z. Wijfjes, L. Smeding, D. van Dalen, A. Cammarata, K. M. Bonger, C. G. Figdor, F. A. Scheeren, M. Verdoes

This paper introduces a CRISPR-based method to engineer hybridoma cells that secrete dual-tagged Fab fragments, enabling site-specific conjugation of multiple cargos.

bioRxiv · Dec 8, 2020Biochemistry

Functional diversification of hybridoma produced antibodies by CRISPR/HDR genomic engineering

J. M. S. van der Schoot, F. L. Fennemann, M. Valente, Y. Dolen, I. M. Hagemans, A. M. D. Becker, C. M. Le Gall, D. van Dalen, A. Cevirgel, J. A. C. van Bruggen, M. Engelfriet, M. F. Fransen, T. Caval, A. E. H. Bentlage, M. Nederend, , F. A. Scheeren

This study presents a CRISPR/HDR platform to engineer hybridoma antibodies for diverse isotypes, formats, and species, enabling functional antibody diversification.

bioRxiv · Feb 15, 2019Bioengineering